BenevolentAI Slashes Jobs And Drug Programs
180 Staff To Leave
The UK firm, which uses artificial intelligence to discover and develop drugs, is hoping to save £45m by halving its workforce and trimming its pipeline.
You may also be interested in...
Deal Snapshot: Two years into a three-year partnership with Lilly, Verge announced another deal, with AstraZeneca’s Alexion, just months after acquiring bragging rights with early clinical data for an AI-discovered product candidate.
The UK computational medicines specialist is listing on the Euronext Amsterdam after linking up with healthcare-focused special purpose acquisition corporation Odyssey which is advised by former Sanofi CEO Olivier Brandicourt.
Mads Krogsgaard Thomsen, CEO of the Novo Nordisk Foundation and the man who supervised the development of semaglutide, describes the unprecedented growth of the obesity market and what might come next for Novo.